Circulating Aldosterone Levels and Disease Severity in Pulmonary Arterial Hypertension

Abstract

OBJECTIVES It is not known whether aldosterone levels are associated with increased mortality in patients with pulmonary arterial hypertension (PAH). The primary goal of this study was to determine whether circulating aldosterone levels predict severity of PAH in terms of hemodynamic characteristics and mortality. METHODS Patients with stable PAH were enrolled at the Baylor PH program. The plasma levels of aldosterone and BNP were measured. Clinical, hemodynamic, and outcome data was collected by chart review. Mean follow up time from study enrollment was 39 ± 102 months. Cox proportional hazards model was used to assess time to death. RESULTS There were 125 PAH patients with plasma aldosterone levels. Median aldosterone level was 9.9 pg/ml (25th–75th percentile: 4.1 pg/ml, 27.1 pg/ml) and median brain natriuretic peptide (BNP) level was 67.5 pg/ml (25th–75th percentile: 31 pg/ml, 225 pg/ml). Aldosterone levels were not significantly associated with BNP levels, six-minute walk distance, Borg dyspnea score, right ventricular systolic pressure, cardiac output and cardiac index. However, the association between aldosterone and right atrial pressure was dependent on mineralocorticoid receptor blocker treatment (Coef. =2.88, 95CI: 1.19, 4.56, p=0.001). By log-rank statistic there was no statistical difference between the survival of patients divided by median aldosterone level (p=0.914). However, there was a significant difference in patient survival between the BNP categories (p<0.001) such that those with high BNP level (>180 pg/mL) had a shorter survival time. CONCLUSIONS The aldosterone level was not associated with increased mortality in PAH but was a marker of disease severity.

High-sensitivity C-reactive protein in heart failure with preserved ejection fraction

“…Although the mechanism cannot be elucidated from this analysis, these findings suggest an association between neurohumoral activation and inflammation in the setting of HFpEF. These biomarkers of neurohumoral activation can be elevated in the setting of both heart failure and pulmonary hypertension and are associated with disease severity and worse prognosis[ 28 , 35 – 38 ]. The relationship between CRP and NT-proBNP, a biomarker with reduced sensitivity for the diagnosis of HF in the setting of obesity, was only significant after adjusting for other variables, such as BMI[ 39 ].…”

Immune regulation of systemic hypertension, pulmonary arterial hypertension, and preeclampsia: shared disease mechanisms and translational opportunities

“…Although most commonly considered in isolation in the context of essential systemic hypertension, hypertension can also present as a feature of multiple conditions, including during pregnancy as a component of preeclampsia (107) and in the pulmonary circulation in the form of pulmonary arterial hypertension (PAH) (138). These disparate hypertensive disorders are driven by a range of physiological changes, including increased arteriolar vascular tone and stiffness (79), as well as alterations in the balance between smooth muscle cell proliferation and apoptosis (45,98), and can share common underlying molecular mechanisms, such as changes in the renin-angiotensin-aldosterone system (RAAS) (90,125,149) and elevations in other soluble vascular effectors like endothelin-1 (18,43,120,127).…”

Early versus late cardiac remodeling during right ventricular pressure load and impact of preventive versus rescue therapy with endothelin-1 receptor blockers

“…In a murine model of heart failure, ERB significantly reduced hypertrophy and collagen deposition (5, 9, 35, 39). ERB also decreased aldosterone-induced cardiomyocyte hypertrophy (36,38). ET-1 interacts with TGF-␤1 to promote myocardial hypertrophy and fibrosis (1,2,21).…”